» Articles » PMID: 32718965

Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline Against Carbapenem-Resistant Escherichia Coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

Overview
Specialty Pharmacology
Date 2020 Jul 29
PMID 32718965
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging carbapenem resistance in , including sequence type 131 (ST131), the leading cause of extraintestinal infections globally, threatens therapeutic efficacy. Accordingly, we determined broth microdilution MICs for three distinctive newer agents, i.e., cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV), plus 11 comparators, against 343 carbapenem-resistant (CR) clinical isolates, then compared susceptibility results with bacterial characteristics and region. The collection comprised 203 U.S. isolates (2002 to 2017) and 141 isolates from 17 countries in Europe, Latin America, and the Asia-West Pacific region (2003 to 2017). Isolates were characterized for phylogenetic group, resistance-associated sequence types (STs) and subsets thereof, and relevant beta-lactamase-encoding genes. CFDC, CZA, and ERV exhibited the highest percent susceptible (82% to 98%) after tigecycline (TGC) (99%); avibactam improved CZA's activity over that of CAZ (11% susceptible). Percent susceptible varied by phylogroup and ST for CFDC and CZA (greatest in phylogroups B2, D, and F, and in ST131, ST405, and ST648). Susceptibility also varied by resistance genotype, being higher with the carbapenemase (KPC) for CZA, lower with metallo-beta-lactamases for CFDC and CZA, and higher with the beta-lactamase CTX-M for ERV. Percent susceptible also varied by global region for CZA (lower in Asia-Pacific) and by U.S. region for ERV (lower in the South and Southeast). Although resistance to comparators often predicted reduced susceptibility to a primary agent (especially CFDC and CZA), even among comparator-resistant isolates the primary-agent-susceptible fraction usually exceeded 50%. These findings clarify the likely utility of CFDC, CZA, and ERV against CR in relation to multiple bacterial characteristics and geographical region.

Citing Articles

activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China.

Liao X, Liang Q, Dai X, Wu S, Duan C, Luo Z Front Microbiol. 2024; 15:1504013.

PMID: 39624714 PMC: 11609169. DOI: 10.3389/fmicb.2024.1504013.


Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.

Harnan S, Kearns B, Scope A, Schmitt L, Jankovic D, Hamilton J Health Technol Assess. 2024; 28(73):1-230.

PMID: 39487661 PMC: 11586833. DOI: 10.3310/YAPL9347.


Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections.

Park S, Baek Y, Kim J, Seong H, Kim B, Kim Y Infect Chemother. 2024; 56(3):308-328.

PMID: 39231504 PMC: 11458495. DOI: 10.3947/ic.2024.0038.


Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.

Woods B, Schmitt L, Jankovic D, Kearns B, Scope A, Ren S Health Technol Assess. 2024; 28(28):1-238.

PMID: 38938145 PMC: 11229178. DOI: 10.3310/YGWR4511.


Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1- isolates with KPC-3 mutants and application of FTIR biotyping.

Castillo-Polo J, Hernandez-Garcia M, Maruri-Aransolo A, de la Vega C, Ruiz-Garbajosa P, Canton R Microbiol Spectr. 2024; 12(4):e0277623.

PMID: 38415657 PMC: 10986490. DOI: 10.1128/spectrum.02776-23.


References
1.
Hanson N . Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002; 40(6):2153-62. PMC: 130804. DOI: 10.1128/JCM.40.6.2153-2162.2002. View

2.
Livorsi D, Chorazy M, Schweizer M, Balkenende E, Blevins A, Nair R . A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States. Antimicrob Resist Infect Control. 2018; 7:55. PMC: 5926528. DOI: 10.1186/s13756-018-0346-9. View

3.
Hackel M, Tsuji M, Yamano Y, Echols R, Karlowsky J, Sahm D . Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017; 61(9. PMC: 5571285. DOI: 10.1128/AAC.00093-17. View

4.
Peirano G, Bradford P, Kazmierczak K, Badal R, Hackel M, Hoban D . Global incidence of carbapenemase-producing Escherichia coli ST131. Emerg Infect Dis. 2014; 20(11):1928-31. PMC: 4214325. DOI: 10.3201/eid2011.141388. View

5.
Livermore D, Mushtaq S, Warner M, Woodford N . In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016; 60(6):3840-4. PMC: 4879382. DOI: 10.1128/AAC.00436-16. View